

Application No. 09/944,564 Page 1

Inventor: Nida Abdul-Ghani Nassief

CLAIMS

1 - 24. (Cancelled)

~~Q/P called~~

25. (New) A pharmaceutical composition consisting essentially of glycophosphopeptidol for oral administration for the treatment of allergy and asthma in dosage and duration which is effective to:

- i- Switch-off the airway eosinophilic inflammation.
- ii- Reduce mucus secretion.
- iii- Reduce symptom scores significantly.
- iv- Restore airways patency as measured by Pulmonary Function Test.

26. ~~dependent~~ (New) A pharmaceutical composition of claim 25, to induce a clinical remission and long-term therapeutic effect in a chronically ill patient.27. ~~dependent~~ (New) A method of treatment of allergy and asthma patients in need of multiple drugs daily, comprising of administering the pharmaceutical composition of claim 25 for a short course of 1-14 days to induce a remission of 3-12 months.28. ~~withdrawn~~ (New) A pharmaceutical composition for the treatment of allergy and asthma consisting essentially of the herbal seeds of *Nigella sativa* to act as a vaccine that is almost identical to Purified Protein Derivative from *Bacillus Calmette Guérin*:

- i- Switch-off the airway eosinophilic inflammation.
- ii- Reduce mucus secretion.
- iii- Reduce symptom scores significantly.
- iv- Restore airways patency as measured by Pulmonary Function Test.

29. ~~withdrawn~~ (New) A pharmaceutical composition vaccine of claim 28, to induce a clinical remission and long-term therapeutic effect in a chronically ill patient suffering from asthma and allergy.30. ~~withdrawn~~ (New) A method of treatment of allergy and asthma patients in need of multiple drugs daily, comprising of administering the pharmaceutical composition of claim 28 for a short course of 1-14 days to induce a remission of 3-12 months.31. ~~withdrawn~~ (New) A pharmaceutical composition vaccine from *Nigella sativa*, to induce a clinical remission and long-term therapeutic effect in patients with Crohn's disease.32. ~~withdrawn~~ (New) A method of treatment of Crohn's disease, comprising of administering the pharmaceutical composition vaccine from *Nigella sativa* for a short course of 1-14 days to induce symptomatic remission.33. ~~withdrawn~~ (New) A pharmaceutical composition vaccine from *Nigella sativa*, to induce a clinical remission and long-term therapeutic effect in patients with influenza and common cold.34. ~~withdrawn~~ (New) A method of treatment of influenza and common cold, comprising of administering the pharmaceutical composition vaccine from *Nigella sativa* for a short course of 1-14 days to induce symptomatic remission.

CLAIMS*Cancelled*

1. Use of glycophosphopeptical for the treatment and/or prophylaxis of allergy/asthma for administration to a mammal such as a human in need of such treatment.

*Cancelled*

2. Use of glycophosphopeptical for the preparation of an asthma/allergy drug , such as extrinsic, intrinsic or mixed asthma, allergic and perennial rhinitis, allergic conjunctivitis, chronic urticaria, atopic dermatitis, and/or laryngeal oedema, to be administered to a mammal such as human in need of such treatment.

*Cancelled*

3. A Pharmaceutical composition comprises glycophosphopeptical, in any pharmacologically active form at a concentration of the extract which is effective as a Th1 stimulating agent.

*Cancelled*

4. A Pharmaceutical composition as claimed in claim 3 further comprising an excipient.

*Cancelled*

5. A method of treatment of diseases caused by type I IgE-mediated hypersensitivity reaction comprising the administration to a mammal such as a human in need of such treatment, of an effective dose of glycophosphopeptical.

*Cancelled*

6. The claim 4 including a dosage regimen as a characterizing feature, administering to a patient suffering from a chronic disease a short-term therapy of 5-20 days, preferably 5 days, of a Th1 stimulating agent, to get a long-term clinical remission of months as a result of selective switching-off of the eosinophilic inflammation.

*Cancelled*

7. The use of the pure seeds of Nigella sativa for the preparation of an asthma and allergy agent in a concentration which was found to perform substantially the same function in substantially the same way to obtain substantially the same results as with glycophosphopeptical.

*Cancelled*

8. A Pharmaceutical composition as claimed in claim 6 further comprising an excipient.

*Cancelled*

9. A medicament as claimed in any preceding claim, which is adapted and/or packaged for

periodic administration to said mammal in doses over a period of 5-20 days, preferably 5 days in doses at least once daily up to ten times/day.

- Cancelled*
10. A medicament as claimed in claim 9, characterized in that each one of said doses comprises up to 2000mgs of said active agent, preferably about 200-1000mgs, of said active agent , adapted for oral administration to said mammal in capsules, or tablets, or lozenges, or as a powder, or a suspension, or a syrup

- Cancelled*
11. A medicament as claimed in any of claims 2, 3, and 7, which is adapted for topical administration to said mammal such as a human, in the form of eye or nasal drops or ointment, also skin or vaginal cream or ointment.

- Cancelled*
12. A kit comprising a medicament as claimed in claim 10 and 11 packaged in separate doses for periodic administration to said mammal such as a human, contains written or printed instructions.

15

- Cancelled*
13. The method of claim 5 and 7 is dependent on the fact that interferon is an in vivo Eosinophilic Chemotactic Factor, and that serum interferon and Th1 lymphocytes are controlling the pre-inflammatory phase of allergic reaction.

20

- Cancelled*
14. The manufacture of a diagnostic kit to diagnose allergy and asthma and to asses the severity Of the disease, using of a quantitative serum interferon concentration measurement.

- Cancelled*
15. The method of claim 5 and 7 wherein the recommended dose of Th1 lymphocytes stimulating agent is sufficient to selectively switch -off the eosinophilic inflammation in the patient's airway.

- Cancelled*
16. The method of claim 5 and 6 wherein Th1 lymphocytes stimulating agents, are capable of stimulating T lymphocytes in culture, comparable to Purified Protein Derivative of BCG, as a classical Cell Mediated Immunity stimulating agent.

Cancelled

17. Use of Th1 stimulating agents for the preparation of an agent for the treatment and/or prophylaxis of diseases characterized by a body immune defensive mechanism is Cell Mediated Immunity as viral respiratory tract infections such as, but not limited to influenza and common cold, other viral infections.

Cancelled

5

18. A method of treatment of viral respiratory tract infections such as, but not limited to influenza and common cold, other viral infections comprising the administration to a mammal such as a human in need of such treatment, of an effective dose of Th1 stimulating agents.

Cancelled

10

19. Use of Th1 stimulating agents for the preparation of an agent for the treatment and/or prophylaxis of diseases characterized by a body immune defensive mechanism is Cell Mediated Immunity as acute and recurrent urinary tract infection, pelvic inflammatory diseases such as but not limited to neuroimmune appendicitis, and cancer.

Cancelled

15

20. A method of treatment of as acute and recurrent urinary tract infection, pelvic inflammatory diseases such as but not limited to neuroimmune appendicitis, and cancer comprising the administration to a mammal such as a human in need of such treatment, of an effective dose of Th1 stimulating agents.

Cancelled

20

21. A method of treatment of crohns disease comprising the administration to a mammal such as a human in need of such treatment, of an effective dose of Th1 stimulating agents in order to stimulate Cell Mediated Immunity.

Cancelled

22. Use of Th1 stimulating agent, for the treatment of crohns disease to be administered to a mammal such as a human in need of such treatment.

Cancelled

23. A method of treatment of facial palsy comprising the administration to a mammal such as a human in need of such treatment, of an effective dose of Th1 stimulating agents.

Cancelled

30

24. Use of Th1 stimulating agent, for the treatment of facial palsy to be administered to a mammal such as a human in need of such therapy.